Emergent Biosolutions, Inc. EBS
$4.49
-1.32%
at last close
Analyst Consensus
- Consensus Rating
- Buy (1 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $10.00
- Implied Upside
- +122.7%
- Price Target Range
- $10.00 – $10.00
- Analysts (12 mo)
- 1
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-10 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $12 → $10 |
| 2026-03-09 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $15 → $12 |
| 2025-12-16 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $15 |
| 2025-09-03 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $15 |
| 2025-04-01 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $15 |
| 2025-03-21 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $15 |
| 2025-03-04 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $15 |
| 2025-01-21 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $15 |
| 2025-01-10 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $15 |
| 2024-12-30 | HC Wainwright & Co.Raghuram Selvaraju |
Initiates coverage on | Buy | $15 |
| 2024-11-07 | BenchmarkRobert Wasserman |
Maintains | Buy | $8 → $12 |
| 2024-09-13 | Rodman & RenshawBrandon Folkes |
Reiterates | Buy | $16 |
| 2024-08-22 | Rodman & Renshaw |
Initiates coverage on | Buy | $16 |
| 2024-08-16 | BenchmarkRobert Wasserman |
Reiterates | Buy | $8 |
| 2024-08-09 | BenchmarkRobert Wasserman |
Reiterates | Buy | $8 |
| 2024-07-03 | BenchmarkRobert Wasserman |
Reiterates | Buy | $8 |
| 2024-07-02 | BenchmarkRobert Wasserman |
Reiterates | Buy | $8 |
| 2024-06-24 | BenchmarkRobert Wasserman |
Reiterates | Buy | $8 |
| 2024-06-21 | BenchmarkRobert Wasserman |
Reiterates | Buy | $8 |
| 2024-06-20 | BenchmarkRobert Wasserman |
Maintains | Buy | $5 → $8 |
| 2024-04-11 | BenchmarkRobert Wasserman |
Reiterates | Buy | $5 |
| 2024-03-07 | BenchmarkRobert Wasserman |
Upgrades | Hold → Buy | $5 |
| 2023-11-20 | JP MorganJessica Fye |
Reinstates | Underweight | — |
| 2023-08-29 | BenchmarkRobert Wasserman |
Downgrades | Buy → Hold | — |
| 2023-05-31 | BenchmarkRobert Wasserman |
Reiterates | Buy | $22 |
| 2023-05-19 | BenchmarkRobert Wasserman |
Reiterates | Buy | $22 |
| 2023-04-10 | BenchmarkRobert Wasserman |
Upgrades | Hold → Buy | $22 |
| 2023-03-17 | JP MorganJessica Fye |
Downgrades | Neutral → Underweight | $23 → $9 |
| 2022-11-10 | BenchmarkRobert Wasserman |
Downgrades | Buy → Hold | — |
| 2022-11-09 | Chardan CapitalKeay Nakae |
Maintains | Buy | $65 → $55 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $4.49
- Market Cap
- $233.29 million
- 52-Week Range
- $4.36 – $14.06
- Average Volume
- 1.08 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.